This review intends to summarize the characteristics of KRAS mutations in solid tumors, update the latest clinical therapeutic strategies, and discuss the mechanisms of drug resistance and tumor development, as well as the immune microenvironment. This evidence concerns the gene KRAS and neoplasm.